MBB Public Markets I LLC Acquires New Shares in Becton, Dickinson and Company $BDX

Key Points

• MBB Public Markets I LLC acquired a new stake in Becton, Dickinson and Company, purchasing 1,405 shares valued at approximately $322,000 in the first quarter.
• The company reported $3.68 EPS for the quarter, exceeding the consensus estimate of $3.40, with a revenue of $5.51 billion, slightly above analyst expectations.
• Shares of Becton, Dickinson and Company have a market cap of $54.89 billion and a dividend yield of 2.2%, with a quarterly dividend announced to be paid on September 30th.

MBB Public Markets I LLC acquired a new stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 1,405 shares of the medical instruments supplier's stock, valued at approximately $322,000.

A number of other hedge funds have also recently added to or reduced their stakes in BDX. Saudi Central Bank acquired a new stake in Becton, Dickinson and Company in the first quarter valued at approximately $26,000. Smallwood Wealth Investment Management LLC acquired a new stake in Becton, Dickinson and Company in the first quarter valued at approximately $27,000. REAP Financial Group LLC grew its stake in Becton, Dickinson and Company by 75.3% in the fourth quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock valued at $29,000 after acquiring an additional 55 shares during the period. Alpine Bank Wealth Management acquired a new stake in Becton, Dickinson and Company in the first quarter valued at approximately $29,000. Finally, Cornerstone Planning Group LLC grew its stake in Becton, Dickinson and Company by 341.4% in the first quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier's stock valued at $29,000 after acquiring an additional 99 shares during the period. Institutional investors and hedge funds own 86.97% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have commented on BDX shares. Wall Street Zen raised Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Barclays decreased their price target on Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating for the company in a report on Tuesday, June 3rd. Morgan Stanley raised their price objective on Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an "overweight" rating in a research note on Monday, August 11th. Wells Fargo & Company upped their target price on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an "equal weight" rating in a research note on Friday, August 8th. Finally, Citigroup lowered shares of Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and reduced their target price for the stock from $217.00 to $185.00 in a research note on Thursday, May 22nd. Four research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $211.44.

Becton, Dickinson and Company Stock Performance

BDX stock traded down $3.34 during midday trading on Friday, hitting $187.23. The company's stock had a trading volume of 1,118,088 shares, compared to its average volume of 1,747,428. The stock's 50-day moving average price is $186.46 and its 200 day moving average price is $191.73. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 1 year low of $163.33 and a 1 year high of $251.99. The stock has a market cap of $53.66 billion, a price-to-earnings ratio of 33.67, a PEG ratio of 1.42 and a beta of 0.27.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, topping the consensus estimate of $3.40 by $0.28. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The business had revenue of $5.51 billion for the quarter, compared to analysts' expectations of $5.50 billion. During the same quarter in the previous year, the firm earned $3.50 earnings per share. The business's revenue was up 10.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. On average, equities analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th will be given a $1.04 dividend. The ex-dividend date of this dividend is Monday, September 8th. This represents a $4.16 annualized dividend and a yield of 2.2%. Becton, Dickinson and Company's payout ratio is currently 74.82%.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, Director Claire Fraser sold 917 shares of the business's stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the sale, the director directly owned 22,226 shares in the company, valued at $4,167,375. The trade was a 3.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Michael David Garrison sold 1,185 shares of the business's stock in a transaction on Friday, July 18th. The shares were sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the sale, the executive vice president owned 4,887 shares in the company, valued at approximately $881,077.23. The trade was a 19.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 2,965 shares of company stock worth $551,536. Insiders own 0.36% of the company's stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.